아스파라기나제 과민성에 대한 전처치와 급속 탈감작의 효용성
Effectiveness of premedication and rapid desensitization in hypersensitivity to L-asparaginase
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: L-asparaginase is a crucial chemotherapeutic agent for the treatment of acute lymphoblastic leukemia. However, hypersensitivity to L-asparaginase is common which limits its clinical use. Methods: We performed 44 cases of premedication and 3 cases of desensitization in 16 patients with hypersensitivity to L-asparaginase. Results: With premedication, 33 cases completed L-asparaginase injection with no hypersensitivity reactions. Eleven cases showed mild hypersensitivity reactions, such as urticaria. Desensitization was performed in 3 cases: in 2 cases, desensitization was successful, and in 1 case the medication was switched to Erwinia asparaginase. Conclusion: Premedication and desensitization appear to be useful in helping patients receive desired doses of L-asparaginase in pediatric patients with acute lymphoblastic leukemia.
Abstract
Purpose: L-asparaginase is a crucial chemotherapeutic agent for the treatment of acute lymphoblastic leukemia. However, hypersensitivity to L-asparaginase is common which limits its clinical use. Methods: We performed 44 cases of premedication and 3 cases of desensitization in 16 patients with hypersensitivity to L-asparaginase. Results: With premedication, 33 cases completed L-asparaginase injection with no hypersensitivity reactions. Eleven cases showed mild hypersensitivity reactions, such as urticaria. Desensitization was performed in 3 cases: in 2 cases, desensitization was successful, and in 1 case the medication was switched to Erwinia asparaginase. Conclusion: Premedication and desensitization appear to be useful in helping patients receive desired doses of L-asparaginase in pediatric patients with acute lymphoblastic leukemia.
참고문헌 (28)
- Graham ML, "Pegaspargase : a review of clinical studies", Adv Drug Deliv Rev, 55, pp.1293~1302 (2003)
- Fu CH, "PEG-asparaginase", Expert Opin Pharmacother, 8, pp.1977~1984 (2007)
- Woo MH, "Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia", Leukemia, 12, pp.1527~1533 (1988)
- Narta UK, "Pharmacological and clinical evaluation of L-asparaginase in the treatment of leukemia", Crit Rev Oncol Hematol, 61, pp.208~221 (2007)
- Pratt CB, "Comparison of daily versus weekly L-asparaginase for the treatment of childhood acute leukemia", J Pediatr, 77, pp.474~483 (1970)
- Cheung NK, "Prognostic significance and clinical utility of antibody measurement", Am J Pediatr Hematol Oncol, 8, pp.99~104 (1986)
- Pratt CB, "Low-dosage asparaginase treatment of childhood acute lymphocytic leukemia", Am J Dis Child, 121, pp.406~409 (1971)
- Haskell CM, "l-asparaginase resistance in human leukemia : asparagine synthetase", Biochem Pharmacol, 18, pp.2578~2580 (1969)
- Soyer OU, "Alternative algorithm for L-asparaginase allergy in children with acute lymphoblastic leukemia", J Allergy Clin Immunol, 123, pp.895~899 (2009)
- Hak LJ, "Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia", Leukemia, 18, pp.1072~1077 (2004)
- Wang B, "Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia(ALL)and lymphoma patients", Leukemia, 17, pp.1583~1588 (2003)
- Castells MC, "Hypersensitivity reactions to chemotherapy : outcomes and safety of rapid desensitization in 413 cases", J Allergy Clin Immunol, 122, pp.574~580 (2008)
- Bonno M, "Rapid desensitization for L-asparaginase hypersensitivity", J Allergy Clin Immunol, 101(4 Pt 1), pp.571~572 (1998)
- Sampson HA, "Second symposium on the definition and management of anaphylaxis : summary report : Second National Institute of Allergy and Infectious Disease", Food Allergy and Anaphylaxis Network symposium, 2006, pp.117, 391~397
- "Version 4.0" (2010)[URL]
- Johansson SG, "A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force", Allergy, 56, pp.813~824 (2001)
- Aronson JK, "Clarification of terminology in drug safety", Drug Saf, 28, pp.851~870 (2005)
- Limsuwan T, "Outcomes and safety of rapid desensitization for chemotherapy hypersensitivity", Expert Opin Drug Saf, 9, pp.39~53 (2010)
- Tallal L, "E. coli L-asparaginase in the treatment of leukemia and solid tumors in 131 children", Cancer, 25, pp.306~320 (1970)
- Clarkson B, "Clinical results of treatment with E. coli L-asparaginase in adults with leukemia, lymphoma, and solid tumors", Cancer, 25, pp.279~305 (1970)
- Moghrabi A, "Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia", Blood, 109, pp.896~904 (2007)
- Silverman LB, "Intravenous PEG asparaginase during remission induction for childhood ALL", Blood, 108, pp.1854~ (2006)
- Raetz EA, "Tolerability and efficacy of L-asparaginase therapy in pediatric patients with acute lymphoblastic leukemia", J Pediatr Hematol Oncol, 32, pp.554~563 (2010)
- Billett AL, "Allergic reactions to Erwinia asparaginase in children with acute lymphoblastic leukemia who had previous allergic reactions to Escherichia coli asparaginase", Cancer, 70, pp.201~206 (1992)
- Salzer WL, "Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy : a report from the Children's Oncology Group", Blood, 122, pp.507~514 (2013)
- Muller HJ, "Use of L-asparaginase in childhood ALL", Crit Rev Oncol Hematol, 28, pp.97~113 (1998)
- Woo MH, "Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia", J Clin Oncol, 18, pp.1525~1532 (2000)
- Larson RA, "Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia", Leukemia, 12, pp.660~665 (1998)